samedan logo
 
 
 
spacer
home > ebr > winter 2017 > time for change
PUBLICATIONS
European Biopharmaceutical Review

Time for Change

Since the early days of Franklin D Roosevelt’s presidency, the ‘first hundred days’ of each new government have been watched with keen anticipation as a roadmap to the new president’s agenda and vision. This period is majestic, magnificent and filled with great expectations.

Biopharmaceutical stocks experienced a dramatic rise in the days immediately following the US election. Pundits interpreted this ‘Trump Effect’ as a harbinger of a new and favourable business climate in America. It did not hurt that Californian voters defeated Proposition 61, the first state price controls on pharmaceuticals.

Executives and investors are pondering the ways in which Trump’s leadership will affect business outcomes. Voters are looking to the incoming president and new Congress to take rapid action in a number of key areas that influence not just specific sectors, but the entire economy. The general pro-business posture and moderated pressure on drug pricing is seen as a considerable win for biotechnology organisations developing expensive treatments for cancer, autoimmune disorders and rare diseases.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Emile Bellott is a member of the EBR Industry Advisory Board, and an industry consultant, with experience in drug discovery, development and pharmaceutical outsourcing.
spacer
Emile Bellott
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Clinical trials in the post Brexit Europe

While negotiations are still ongoing, the structure of the post-Brexit medicine testing and approval process is still unclear, and the UK government has so far ruled out an extension to the transition period which is due to come to an end at the end of this year.
More info >>

White Papers

Igb Tamper Evident Folding Box

IGB

The easiest, safest and less expensive solution in compliance with what requires Dir. 62/2011/EU, FDA and TGA.
More info >>

 
Industry Events

BIO-Europe Digital

26-29 October 2020, Digitally delivered

Global connections are more important than ever. With the same powerful one-to-one partnering and valuable content, BIO-Europe Digital continues to help you drive your life science partnering forward.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement